News for CHRS Stock

Coherus Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025 Coherus Completes Strategic Transformation to Coherus Oncology, Focusing Exclusively on Innovative Cancer Therapeutics Coherus Announces Clinical Collaboration with STORM Therapeutics to Evaluate STC-15 in Combination with LOQTORZI® (toripalimab-tpzi) Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update Coherus to Report First Quarter 2025 Financial Results on May 12, 2025 Coherus to Participate in Upcoming Investor Conferences Coherus Presents Promising Early Clinical Data from Phase 1 Dose Expansion Study of CHS-114 in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at AACR 2025 Coherus Completes Strategic Transformation with Successful Divestiture of UDENYCA® Franchise Coherus Announces Repurchase of Approximately $170 Million of Convertible Notes Coherus to Present Data from a Phase 1 Dose Expansion Study of CHS-114, a Cytolytic Antibody Targeting Chemokine Receptor 8 (CCR8), at the 2025 American Association for Cancer Research (AACR) Annual Meeting Coherus BioSciences Reports Fourth Quarter, Full Year 2024 Financial Results and Provides Business Update Coherus to Report Fourth Quarter and Full Year 2024 Financial Results on March 10, 2025 Coherus Management to Participate at the 45th Annual TD Cowen Health Care Conference Coherus Presents Final Phase 2 Clinical Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025 Coherus Management to Present at the 43rd Annual J.P. Morgan Healthcare Conference Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025 Coherus Announces Agreement to Divest UDENYCA® Franchise for up to $558 million to Intas Pharmaceuticals Ltd. Coherus Management to Participate in the 2024 Citi Global Healthcare Conference Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update Coherus to Report Third Quarter 2024 Financial Results on November 6, 2024 Coherus BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update Coherus to Report Second Quarter 2024 Financial Results on August 8, 2024 Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction Coherus BioSciences Appoints Rita Karachun, CPA, CGMA to its Board of Directors Coherus Management to Present at the 2024 Jefferies Global Healthcare Conference Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting Coherus Management to Present at the TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI® (toripalimab-tpzi) with ENB Therapeutics' ENB-003 for the Treatment of Ovarian Cancer Coherus to Report First Quarter 2024 Financial Results on May 9, 2024 Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024 Coherus Completes Divestiture of Ophthalmology Franchise Coherus BioSciences Announces New Employment Inducement Grants Coherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv Coherus Amends Term Loan Agreement with Pharmakon Advisors, LP Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers Symposium INOVIO and Coherus Announce Clinical Collaboration to Advance Development of INO-3112 in Combination with LOQTORZI™ (toripalimab-tpzi) Coherus BioSciences Management to Present at the 42nd Annual J.P. Morgan Healthcare Conference Coherus Announces U.S. Launch of LOQTORZI™ Coherus Announces FDA Approval of UDENYCA ONBODY™, a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv Coherus BioSciences Announces New Employment Inducement Grants Coherus Announces Updated NCCN Clinical Practice Guidelines Positioning LOQTORZI™ (toripalimab-tpzi) as Preferred Category 1 Regimen for First-Line Treatment of Cancer of the Nasopharynx Coherus BioSciences Announces CFO Transition Plans Coherus Presents Phase 1/2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2023 ESMO Immuno-Oncology Congress Coherus and Junshi Biosciences Announce Publication of Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Trial Evaluating LOQTORZI™ (toripalimab-tpzi) as Treatment for Nasopharyngeal Carcinoma, in the Journal of the American Medical Association Coherus BioSciences Reports Third Quarter 2023 Financial Results and Business Highlights Coherus Presents Data from Next-generation Immuno-oncology Programs at 38th Annual Meeting of Society for Immunotherapy of Cancer (SITC) Coherus BioSciences to Participate at Upcoming November Investor Conferences Coherus BioSciences to Report Third Quarter 2023 Financial Results on November 6, 2023 Coherus and Junshi Biosciences Announce FDA Approval of LOQTORZI™ (toripalimab-tpzi) in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) Coherus BioSciences Announces New Employment Inducement Grants Coherus Announces Resubmission of Biologics License Application (BLA) Supplement for UDENYCA® ONBODY™ CIMERLI® (ranibizumab-eqrn) Sales Exceed 100,000 Doses in First Year of Launch Coherus Applauds Congressional Designation of September 30th as Rare Cancer Day Coherus Announces Three Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) FDA Issues Complete Response Letter (CRL) for UDENYCA® ONBODY™ Biologics License Application Solely Due to an Ongoing Review of Inspection Findings at a Third-Party Filler; Coherus Also Announces Completion of Toripalimab FDA Inspections Coherus BioSciences Announces New Employment Inducement Grants Coherus Completes Surface Oncology Acquisition Coherus BioSciences to Participate at Upcoming September Investor Conferences Coherus BioSciences Announces New Employment Inducement Grants Coherus BioSciences Reports Second Quarter 2023 Financial Results and Business Highlights Coherus BioSciences to Report Second Quarter 2023 Financial Results on August 02, 2023 Coherus BioSciences Announces New Employment Inducement Grants Coherus BioSciences Appoints Dr. Michael Ryan to its Board of Directors Coherus and Superior Biologics Announce National Distribution Agreement for YUSIMRY™ Coherus Launches YUSIMRY™, a Biosimilar of Humira®, at $995 per Carton in U.S. Coherus BioSciences Announces New Employment Inducement Grants Coherus to Acquire Surface Oncology Coherus Announces Positive Final Overall Survival Results of JUPITER-02 Phase 3 Trial Evaluating Toripalimab in Nasopharyngeal Carcinoma Mark Cuban Cost Plus Drug Company joins forces with Coherus to make YUSIMRY™, a HUMIRA® biosimilar, available to patients Coherus Announces Industry-Wide Lowest List Price for Adalimumab Biosimilar YUSIMRY™ (adalimumab-aqvh) Launching in July 2023 Coherus Announces U.S. Launch of UDENYCA® Autoinjector Coherus Prices Public Offering of Common Stock Coherus Announces Proposed Public Offering of Common Stock Coherus BioSciences Reports First Quarter 2023 Financial Results and Business Highlights Coherus BioSciences to Present at Upcoming Investor Conferences in May Coherus BioSciences to Report First Quarter 2023 Financial Results on May 8, 2023 Coherus and Junshi Biosciences Announce Toripalimab Studies to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting Coherus BioSciences Reports Fourth Quarter and Full Year 2022 Results FDA Approves UDENYCA® Autoinjector Coherus BioSciences to Present at Upcoming Investor Conferences in March Coherus BioSciences to Report Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023 Coherus and Junshi Biosciences Announce Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Clinical Trial Evaluating Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma Coherus Granted Permanent, Product-Specific Q-Code for CIMERLI® (ranibizumab-eqrn) from the Centers for Medicare and Medicaid Services Coherus BioSciences Announces New Employment Inducement Grants Coherus Agrees to Acquire Exclusive U.S. Commercial Rights to Eylea® Biosimilar FYB203 from Klinge Biopharma Coherus BioSciences Management to Present at the 41st Annual J.P. Morgan Healthcare Conference Coherus and Junshi Biosciences Share Update on the FDA Review of the Biologics License Application (BLA) for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) Coherus BioSciences Reports Third Quarter 2022 Results and Provides Business Update Coherus BioSciences to Report Third Quarter 2022 Financial Results on November 8th, 2022 Coherus and Junshi Biosciences Announce Publication of Positive Results from CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer, in the Journal of Clinical Oncology Coherus to Launch CIMERLI™ (ranibizumab-eqrn) in the United States on October 3, 2022 Coherus BioSciences Management to Present at H.C. Wainwright 24th Annual Global Investment Conference Coherus BioSciences Announces New Employment Inducement Grants Coherus BioSciences Reports Second Quarter 2022 Results and Provides Business Update FDA Approves Coherus’ CIMERLI™ (ranibizumab-eqrn) as the First and Only Interchangeable Biosimilar to Lucentis® for All Five Indications, with 12 Months of Interchangeability Exclusivity Coherus BioSciences Announces New Employment Inducement Grants Coherus BioSciences to Report Second Quarter 2022 Financial Results on August 4th, 2022 Coherus and Junshi Biosciences Announce FDA Acceptance of Resubmission of BLA for Toripalimab for the Treatment of Nasopharyngeal Carcinoma Coherus BioSciences Announces New Employment Inducement Grants Coherus BioSciences Appoints Dr. Jill O’Donnell-Tormey to its Board of Directors Coherus BioSciences Management to Present at Upcoming Investor Conferences Coherus BioSciences Reports First Quarter 2022 Results Coherus BioSciences Appoints Charlie Newton to Board of Directors Coherus BioSciences Announces New Employment Inducement Grants Coherus and Junshi Biosciences Receive Complete Response Letter from U.S. FDA for Toripalimab BLA CORRECTION - Coherus BioSciences to Report First Quarter 2022 Financial Results on May 5th, 2022 Coherus BioSciences to Report First Quarter 2022 Financial Results on May 5th, 2022 Coherus and Junshi Biosciences Announce PD-1 Inhibitor Toripalimab Granted Orphan Drug Designation for Small Cell Lung Cancer in the United States Coherus and Junshi Biosciences Present Results of Phase 3 Study of Toripalimab in First Line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma at 2022 AACR Annual Meeting Coherus BioSciences Announces New Employment Inducement Grants Coherus Highlights Anticipated New Product Launches and Immuno-oncology Growth Strategy at Analyst Day Event Coherus BioSciences to Highlight New Product Pipeline, Cancer Immunotherapy Development Plans at March 29, 2022 Analyst Day Event Coherus BioSciences Appoints Rosh Dias, MD, MRCP, Chief Medical Officer Junshi Biosciences and Coherus Announce Presentation of Positive Results from CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer, at March ASCO Plenary Series Coherus Management to Present at Upcoming Investor Conferences Coherus and Junshi Biosciences Announce Positive Results from Phase 3 Esophageal Cancer Study of Toripalimab Published in Cancer Cell Coherus BioSciences Reports Fourth Quarter and Full Year 2021 Results Coherus Names Paul Reider Chief Commercial Officer Coherus BioSciences Announces New Employment Inducement Grants Coherus BioSciences to Report Fourth Quarter and Full Year 2021 Financial Results on February 17th, 2022 Coherus BioSciences Appoints Health Care Payer Expert Lee N. Newcomer, M.D., to Board of Directors Coherus and Junshi Biosciences Expand Immuno-Oncology Collaboration to Include TIGIT-Targeted Antibody Coherus BioSciences Secures Credit Financing with Pharmakon Advisors Coherus BioSciences Management to Present at the 40th Annual J.P. Morgan Healthcare Conference Coherus Announces U.S. FDA Approval of YUSIMRY™ (adalimumab-aqvh) Coherus BioSciences Appoints Theresa LaVallee, Ph.D., Chief Development Officer Coherus BioSciences Announces New Employment Inducement Grants Coherus and Junshi Biosciences Announce Positive Interim Overall Survival Results of CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer Coherus and Junshi Biosciences Announce Toripalimab Granted Orphan Drug Designation in the United States for Esophageal Cancer Coherus BioSciences Announces New Employment Inducement Grants Coherus BioSciences Reports Third Quarter 2021 Results Coherus BioSciences Announces CMS Has Extended Enhanced Medicare Reimbursement for UDENYCA® in the 340B Hospital Setting Through Year-End 2022 Coherus and Junshi Biosciences Announce FDA Acceptance of BLA Filing for Toripalimab for Treatment of Nasopharyngeal Carcinoma Coherus BioSciences to Report Third Quarter 2021 Financial Results on November 8th Coherus BioSciences Mourns the Passing of Board Member Alan C. Mendelson Coherus Announces Positive Results of UDENYCA® On-Body Injector Clinical Trial Positive Results of Clinical Trial Comparing Coherus’ Ranibizumab Biosimilar Candidate CHS-201 to Reference Product Lucentis® (Ranibizumab) in the Treatment of Neovascular (Wet) Age-Related Macular Degeneration (nAMD) Presented at Retina Society Annual Scientific Meeting Coherus Announces BLA Filing for Lucentis® (ranibizumab) Biosimilar Candidate Accepted by FDA for Review Coherus BioSciences Mourns the Passing of Board Member Dr. Samuel Nussbaum Coherus BioSciences Announces New Employment Inducement Grants Coherus and Junshi Biosciences to Present Positive Progression Free Survival and Overall Survival Results from JUPITER-06, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Advanced Esophageal Squamous Cell Carcinoma Coherus and Junshi Biosciences Announce Results from Phase 3 Study of Toripalimab Published in September Issue of Nature Medicine Positive Interim Results of CHOICE-01 Study Evaluating Coherus' and Junshi Biosciences’ Toripalimab for First Line Treatment of Non-Small Cell Lung Cancer Presented at World Conference on Lung Cancer Coherus Management to Present at the H.C. Wainwright 23rd Annual Global Investment Conference Coherus BioSciences Announces Upcoming Medical Conference Presentations Coherus and Junshi Biosciences Announce Completion of Rolling BLA Submission to U.S. FDA for Toripalimab for the Treatment of Nasopharyngeal Carcinoma Coherus BioSciences Announces New Employment Inducement Grants Coherus and Junshi Biosciences Announce Positive Interim Results of CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer Junshi Biosciences and Coherus Announce U.S. FDA Breakthrough Therapy Designation Granted for Toripalimab for 1st Line Treatment of Nasopharyngeal Carcinoma Coherus BioSciences Reports Second Quarter 2021 Financial Results and Immuno-oncology and Biosimilar Pipeline Progress Coherus BioSciences to Report Second Quarter 2021 Financial Results on August 5th Coherus BioSciences Names Physician-Scientist Ildiko Csiki, M.D., Ph.D., Chair of its Scientific Advisory Board Coherus BioSciences Announces New Employment Inducement Grants Coherus and Junshi Biosciences to Host Virtual Investor Event to Discuss Toripalimab and ASCO 2021 Highlights Coherus and Junshi Biosciences Announce Toripalimab in Combination with Chemotherapy Met Primary Progression Free Survival (PFS) Endpoint as First Line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) Coherus BioSciences to Present at the Bank of America Health Care Conference Coherus BioSciences Reports First Quarter 2021 Financial Results and Immuno-oncology and Biosimilar Pipeline Progress Coherus BioSciences Announces New Employment Inducement Grants Coherus BioSciences to Report First Quarter 2021 Financial Results on May 6th Junshi Biosciences and Coherus Announce Toripalimab First-Line Nasopharyngeal Carcinoma Clinical Data to be Showcased in Plenary Session at 2021 ASCO Annual Meeting Coherus Announces Toripalimab Achieved Primary Endpoints of Progression Free Survival and Overall Survival in Interim Analysis of Phase 3 Clinical Trial in First-Line Esophageal Squamous Cell Carcinoma Coherus Announces Closing of Sale of Common Stock to Immuno-Oncology Partner Junshi Biosciences Junshi Biosciences and Coherus BioSciences Announce Initiation of Rolling Submission of BLA for Toripalimab to the U.S. FDA for the Treatment of Nasopharyngeal Carcinoma Coherus Management to Present at Upcoming Investor Conferences Coherus BioSciences Reports Fourth Quarter and Full Year 2020 Financial Results Coherus BioSciences to Report Fourth Quarter and Full Year 2020 Financial Results on February 24th Coherus BLA Filing for Adalimumab Biosimilar Candidate Accepted by FDA for Review Coherus Announces CFO Transition Plans Coherus BioSciences to expand late-stage pipeline to immuno-oncology with in-license of Junshi Biosciences’ PD-1, toripalimab, in United States and Canada Coherus BioSciences Announces New Employment Inducement Grants Coherus BioSciences Appoints Alan Mendelson and Mark Stolper to Board of Directors Coherus BioSciences Management to Present at the 39th Annual J.P. Morgan Healthcare Conference Coherus BioSciences Announces New Employment Inducement Grants Coherus BioSciences Announces New Employment Inducement Grants Coherus BioSciences Reports Third Quarter 2020 Financial Results Coherus BioSciences to Report Third Quarter Financial Results on November 5th Coherus BioSciences Announces New Employment Inducement Grants Coherus BioSciences Announces New Employment Inducement Grants Coherus BioSciences Announces New Employment Inducement Grants Coherus BioSciences Reports Second Quarter 2020 Financial Results Coherus BioSciences Appoints Kimberly Tzoumakas, J.D. to Board of Directors Coherus BioSciences Announces New Employment Inducement Grants Coherus BioSciences Management to Present at BofA Securities 2020 Health Care Conference Coherus BioSciences Announces New Employment Inducement Grants Coherus BioSciences Reports First Quarter 2020 Financial Results